Bioactive sulfoximines: Syntheses and properties of Vioxx® analogs

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 16, 2011, Pages 4888-4890

  Park, Seong Jun ^a   Buschmann, Helmut ^b   Bolm, Carsten ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Sperberweg 15   (Germany)

Author keywords

COX 2 selective inhibitor (COXIB); hERG activity; Sulfoximine; Vioxx (Rofecoxib)

Indexed keywords

CYCLOOXYGENASE 2; IMINE; POTASSIUM CHANNEL HERG; ROFECOXIB; SULFOXIMINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION;

EID: 79960903495     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.06.029     Document Type: Article

References (45)

1. L.J. Marnett Annu. Rev. Pharmacol. Toxicol. 49 2009 265
2. W.A. Ray, C.M. Stein, J.R. Daugherty, K. Hall, P.G. Arbogast, and M.R. Griffin Lancet 360 2002 1071
3. J. Zhang, E.L. Ding, and Y. Song JAMA 296 2006 1619
4. P. McGettigan, and D. Henry JAMA 296 2006 1633
5. S.D. Solomon, J.J.V. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A. Zauber, E. Hawk, and M. Bertagnolli N. Eng. J. Med. 352 2005 1071
6. F. Andersohn, R. Schade, S. Suissa, and E. Garbe Stroke 37 2006 1725
7. M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, M. Redston, S.D. Solomon, K. Kim, J. Tang, R.B. Rosenstein, J. Wittes, D. Corle, T.M. Hess, G.M. Woloj, F. Boisserie, W.F. Anderson, J.L. Viner, D. Bagheri, J. Burn, D.C. Chung, T. Dewar, T.R. Foley, N. Hoffman, F. Macrae, R.E. Pruitt, J.R. Saltzman, B. Salzberg, T. Sylwestrowicz, G.B. Gordon, and E.T. Hawk N. Eng. J. Med. 355 2006 873
8. P.M. Kearney, C. Baigent, J. Godwin, H. Halls, J.R. Emberson, and C. Patrono Br. Med. J. 332 2006 1302
9. D.H. Solomon, J. Avorn, T. Stürmer, R.J. Glynn, H. Mogun, and S. Schneeweiss Arthritis Rheum. 54 2006 1378
10. H.R. Bentley, E.E. McDermott, J. Pace, J.K. Whitehead, and T. Moran Nature 163 1949 675
11. H.R. Bentley, E.E. McDermott, J. Pace, J.K. Whitehead, and T. Moran Nature 165 1950 150
12. H.R. Bentley, McDermott, and J.K. Whitehead Nature 165 1950 735
13. C.R. Johnson Acc. Chem. Res. 6 1973 341
14. M. Reggelin, and C. Zur Synthesis 2000 1
15. R. Bentley Chem. Soc. Rev. 34 2005 609
16. C. Worch, A.C. Mayer, and C. Bolm T. Toru, C. Bolm, Organosulfur Chemistry in Asymmetric Synthesis 2008 Wiley/VCH Weinheim 209
17. M. Harmata Chemtracts 16 2003 660
18. H. Okamura, and C. Bolm Chem. Lett. 33 2004 482
19. (c) C. Bolm D. Enders, K.-E. Jaeger, Asymmetric Synthesis with Chemical and Biological Methods 2007 Wiley/VCH Weinheim 149
20. For a recent example, where buthionine sulfoximine (BSO) was applied as inhibitor for the glutathione biosynthesis, see: K. Takahashi, R. Tatsunami, T. Oba, and Y. Tampo Biol. Pharm. Bull. 33 2010 556
21. For the initial demonstration, that BSO blocks the GSH synthesis by inhibiting the γ-glutamylcysteine synthetase, see: A. Meister Science 220 1983 472
22. For a recent example of the patent literature related to agrochemicals, see: Paulini, R.; Breuninger, D.; vonDeyn, W.; Bastiaans, H. M. M.; Beyer, C.; Anspaugh, D. D.; Oloumi-Sadeghi, H. WO 156336 A1, 2009 (BASF AG).
23. For a recent example of the patent literature related to medicinal chemistry, see: von Nussbaum, F.; Karthaus, D.; Anlauf, S.; Delbeck, M.; Li, V. M.-J.; Meibom, D.; Lustig, K.; Schneider, D. WO 115548 A1, 2010 (Bayer Schering Pharma AG).
24. M. Kahraman, S. Sinishtaj, P.M. Dolan, T.W. Kensler, S. Peleg, U. Saha, S.S. Chuang, G. Bernstein, B. Korczak, and G.H. Posner J. Med. Chem. 47 2004 6854
25. A. Raza, Y.Y. Sham, and R. Vince Bioorg. Med. Chem. Lett. 18 2008 5406
26. Lücking U.; Siemeister, G.; Jautelat, R. WO 099974 A1, 2006 (Schering AG).
27. D.P. Walker, M.P. Zawistoski, M.A. McGlynn, J.-C. Li, D.W. Kung, P.C. Bonnette, A. Baumann, L. Buckbinder, J.A. Houser, J. Boer, A. Mistry, S. Han, L. Xing, and A. Guzman-Perez Bioorg. Med. Chem. Lett. 19 2009 3253
28. For the relationship between hERG inhibition and cardiovascular safety, see: R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, M.A. Konstam, and J.A. Baron N. Eng. J. Med. 352 2005 1092
29. Friderichs, E.; Christoph, T.; Buschmann, H. 2007. Analgesics and Antipyretics. Ullmann's Encyclopedia of Industrial Chemistry.
30. M. Thérien, J.Y. Gauthier, Y. Leblanc, S. Léger, H. Perrier, P. Prasit, and Z. Wang Synthesis 2001 1778
31. O.G. Mancheño, and C. Bolm Org. Lett. 9 2007 2951
32. O.G. Mancheño, O. Bistri, and C. Bolm Org. Lett. 9 2007 3809
33. A. Pandey, and C. Bolm Synthesis 2010 2922
34. P. Stoss, and G. Satzinger Tetrahedron Lett. 4 1973 267
35. J. Swigert, and K.G. Taylor J. Am. Chem. Soc. 93 1971 7338
36. C.R. Johnson, C.W. Schroeck, and J.R. Schanklin J. Am. Chem. Soc. 95 1973 7424
37. C.S. Shiner, and A.H. Berks J. Org. Chem. 53 1988 5542
38. 50 values were 0.0424 and 0.156 μM, respectively. Details are given in the Supplementary data. The following references were relevant for those experiments: C.-C. Chan, S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, J. Evans, A.W. Ford-Hutchinson, M.J. Forrest, J.Y. Gauthier, R. Gordon, M. Gresser, J. Guay, S. Kargman, B. Kennedy, Y. Leblanc, S. Leger, J. Mamcini, G.P. O'Neill, M. Ouellet, D. Patrick, M.D. Percival, H. Perrier, P. Prasit, I. Rodger, P. Tagari, M. Therien, P. Vickers, D. Visco, Z. Wang, J. Webb, E. Wong, L.-J. Xu, R.N. Young, R. Zamboni, and D. Riendeau J. Pharmacol. Exp. Ther. 290 1999 551
39. D.C. Swinney, A.Y. Mak, J. Barnett, and C.S. Ramesha J. Biol. Chem. 272 1997 12393
40. D. Riendeau, S. Charleson, W. Cromlish, J.A. Mancini, E. Wong, and J. Guay Can. J. Physiol. Pharmacol. 75 1997 1088
41. T.D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J.A. Mitchell, and J.R. Vane Proc. Natl. Acad. Sci. U.S.A. 96 1999 7563
42. The biochemical assays for the determinations of the hERG blocking potencies were performed by Cytocentrics, Rostock, Germany. Quinidine served as reference compound. Details are given in the Supplementary data. The following references were relevant for those experiments: M.C. Sanguinetti, C. Jiang, M.E. Curran, and M.T. Keating Cell 81 1995 299
43. H.J. Witchel Expert Opin. Ther. Targets 11 2007 321
44. S. Mohammad, Z. Zhou, Q. Gong, and C.T. January Am. J. Physiol. 273 1997 2534
45. Here, only racemic sulfoximines have been investigated. Optically active products should be accessible via the corresponding known sulfoxides. For their preparation, see: F. Caturla, M. Amat, R.F. Reinoso, M. Córdoba, and G. Warrellow Bioorg. Med. Chem. Lett. 16 2006 3209